Ralimetinib, soluble in warmed DMSO, warmed water and ethanol, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates.
Ralimetinib is investigated for its ability to inhibit p38 MAPK and its implications in treating inflammatory and oncological diseases.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.